A single molecule designed to target NLRP3, the driver of neuroinflammation that causes optic neuropathy and elevated IOP simultaneously 16 Administered via intravitreal injection Disease Modifying NLRP3 Inhibitor IOP Lowering Small Molecule Glaucoma “Duet”: Biopolymer with 2 Small Molecules NLRP3 inhibitor + IOP lowering agent A high molecular weight, phosphorylcholine - based biopolymer that enables extended ocular residence time for the potential of a quarterly dosed intravitreal therapy Targets the underlying neuroinflammation that drives optic neuropathy. May also provide additional IOP lowering effects through TM modulation Extended Durability